Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

User encourages taking finasteride for hair loss, stating rare permanent side effects. Replies discuss experiences with finasteride, side effects, effectiveness, and alternative treatments.

Upcoming hair loss treatments are in various trial phases, with some expected by 2034-36. Current reliance remains on finasteride and minoxidil, with hopes for future non-hormonal solutions.

PP405 is considered a potential alternative to minoxidil and finasteride, but its effectiveness and safety are still uncertain. Many users suggest sticking with proven treatments like finasteride and minoxidil due to the lack of long-term data on PP405.

1 mg of finasteride is commonly prescribed because it is more effective for a larger number of people compared to lower doses, despite only slightly reducing serum DHT more than 0.2 mg. Serum DHT and scalp DHT are different, and 1 mg is believed to reduce scalp DHT more effectively, contributing to better hair growth results.

Finasteride and Dutasteride are under review in the EU due to concerns about side effects like depression, but they are unlikely to be banned. Access to these medications varies, with easier availability in the UK compared to some EU countries.

The conversation discusses the effects of finasteride on hair loss and its potential neurological and sexual side effects. Users share personal experiences, with some reporting positive outcomes and others expressing concerns about cognitive function.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A user is seeking recommendations for a dermatologist in Houston specializing in alopecia areata for her daughter. A doctor actively researching alopecia areata in young people was suggested.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

Oral dutasteride 0.5 mg combined with oral minoxidil 2.5 mg is highly effective for male androgenetic alopecia, showing over 60% improvement and 98% stabilization at 6 months, with low adverse event rates. Patients with severe baseline conditions respond better and faster to this treatment.

Finasteride, dutasteride, and minoxidil are discussed as treatments for male pattern baldness. Finasteride and dutasteride are effective DHT blockers, while minoxidil is necessary for regrowth but must be used consistently.

Hair loss requires proper diagnosis as it can have various causes, and treatments like finasteride, minoxidil, and dutasteride are often used. Many people express frustration with dermatologists and turn to self-research and alternative sources for treatment.

COVID and COVID vaccination can trigger hair loss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Finasteride is prescribed at 1mg because it is FDA-approved and proven effective, despite evidence that 0.2mg may similarly reduce DHT. The 1mg dose is more effective for hair growth, and lower doses are less available.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

Microneedling is supported by research as an effective adjuvant treatment for hair loss, especially when combined with Minoxidil or Finasteride, with minimal side effects if done properly. Concerns about long-term safety and potential risks like infection or fibrosis remain, but many users report positive results.

A user reported better hair regrowth with 5 mg oral minoxidil and 1 mg dutasteride than with finasteride and topical minoxidil, calling topical minoxidil a scam. Replies varied, with some defending topical minoxidil, questioning the user's application method, and suggesting that previous treatments might be contributing to the observed results.

New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.

South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.

A 21-year-old male has been experiencing persistent hair loss despite using treatments like dutasteride, finasteride, RU58841, minoxidil, and ketoconazole. Suggestions include checking for hormonal issues, nutritional deficiencies, or allergies, and consulting a doctor for professional advice.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

Oral minoxidil 2.5mg is generally as effective as 5mg for hair loss with fewer side effects, making it a preferred starting dose. Some users experience side effects like dizziness and water retention at 5mg, and switching to topical minoxidil or combining it with finasteride is suggested for better results.

The user reported positive results using KX-826 0.5% twice daily for hair loss, noting progress in the temple area with no systemic side effects. They avoided finasteride and minoxidil due to concerns about side effects and inconvenience, respectively, and used ketoconazole shampoo for seborrheic dermatitis.

The user shared their 4-month results using topical minoxidil 5%, finasteride 0.5%, and tretinoin 0.02%, noting progress on the top/crown but not on the temples. They plan to continue with topical treatments, considering them safer than oral options.

Hair serums like The Ordinary and Vichy are seen as minor additions to hair loss treatments but are not considered effective on their own compared to well-studied options like Minoxidil and Finasteride. They may improve scalp health or hair strand quality but are not reliable for significant hair regrowth or combating male pattern baldness.

Oral minoxidil can cause rare facial bloating, especially at higher doses and in women. Reducing sodium intake, drinking more water, and adjusting the dose can help manage side effects.